Furthermore, acquired KRAS mutations after adagrasib monotherapy, including G12D/R/V/W, G13D, Q61H, R68S, H95D/Q/R, and Y96C, were detected in the analysis of 27 patients with NSCLC, 10 with colorectal cancer, and one with appendiceal cancer who achieved tumor reduction, in addition to EGFR or MET amplification and other MAPK kinase gene mutations.96 This evidence concerns the gene KRAS and non-small cell lung carcinoma.